Quantitative Analysis of Complex Drug-Drug Interactions between Cerivastatin and Metabolism/Transport Inhibitors Using Physiologically Based Pharmacokinetic Modeling
暂无分享,去创建一个
Yuichi Sugiyama | Kota Toshimoto | Y. Sugiyama | Soo-Jin Kim | S. Kim | K. Toshimoto | T. Yoshikado | Yoshiaki Yao | Yoshiaki Yao | Takashi Yoshikado
[1] Y. Sugiyama,et al. Analysis of Nonlinear and Nonsteady State Hepatic Extraction with the Dispersion Model Using the Finite Difference Method , 1998, Journal of Pharmacokinetics and Biopharmaceutics.
[2] K. Maeda,et al. Substrate-Dependent Inhibition of Organic Anion Transporting Polypeptide 1B1: Comparative Analysis with Prototypical Probe Substrates Estradiol-17β-Glucuronide, Estrone-3-Sulfate, and Sulfobromophthalein , 2013, Drug Metabolism and Disposition.
[3] L Fritsche,et al. Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine‐treated kidney transplant recipients , 1999, Clinical pharmacology and therapeutics.
[4] L. Benet,et al. The Extended Clearance Concept Following Oral and Intravenous Dosing: Theory and Critical Analyses , 2018, Pharmaceutical Research.
[5] Yuichi Sugiyama,et al. Quantitative Analysis of Complex Drug-Drug Interactions Between Repaglinide and Cyclosporin A/Gemfibrozil Using Physiologically Based Pharmacokinetic Models With In Vitro Transporter/Enzyme Inhibition Data. , 2017, Journal of pharmaceutical sciences.
[6] Akihiko Konagaya,et al. Cluster Newton Method for Sampling Multiple Solutions of Underdetermined Inverse Problems: Application to a Parameter Identification Problem in Pharmacokinetics , 2014, SIAM J. Sci. Comput..
[7] Sebastian Polak,et al. Population-Based Mechanistic Prediction of Oral Drug Absorption , 2009, The AAPS Journal.
[8] Yoshiyuki Asai,et al. Integrative and theoretical research on the architecture of a biological system and its disorder , 2019, The Journal of Physiological Sciences.
[9] A. D. Rodrigues,et al. GLUCURONIDATION CONVERTS GEMFIBROZIL TO A POTENT, METABOLISM-DEPENDENT INHIBITOR OF CYP2C8: IMPLICATIONS FOR DRUG-DRUG INTERACTIONS , 2006, Drug Metabolism and Disposition.
[10] Y. Lai,et al. Hepatic Disposition of Gemfibrozil and Its Major Metabolite Gemfibrozil 1-O-β-Glucuronide. , 2015, Molecular pharmaceutics.
[11] Kiyomi Ito,et al. Effect of buffer conditions on CYP2C8-mediated paclitaxel 6α-hydroxylation and CYP3A4-mediated triazolam α- and 4-hydroxylation by human liver microsomes , 2016, Xenobiotica; the fate of foreign compounds in biological systems.
[12] Y. Sugiyama,et al. Method for predicting the risk of drug–drug interactions involving inhibition of intestinal CYP3A4 and P-glycoprotein , 2009, Xenobiotica; the fate of foreign compounds in biological systems.
[13] E. Wooltorton. Bayer pulls cerivastatin (Baycol) from market. , 2001, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[14] U. Hofmann,et al. Characterisation of cerivastatin as a P-glycoprotein substrate: studies in P-glycoprotein-expressing cell monolayers and mdr1a/b knock-out mice , 2004, Naunyn-Schmiedeberg's Archives of Pharmacology.
[15] B Agoram,et al. Predicting the impact of physiological and biochemical processes on oral drug bioavailability. , 2001, Advanced drug delivery reviews.
[16] A. D. Rodrigues,et al. Quantitative Rationalization of Gemfibrozil Drug Interactions: Consideration of Transporters-Enzyme Interplay and the Role of Circulating Metabolite Gemfibrozil 1-O-β-Glucuronide , 2015, Drug Metabolism and Disposition.
[17] Bertram Pitt,et al. Withdrawal of cerivastatin from the world market , 2001, Current controlled trials in cardiovascular medicine.
[18] Y. Sugiyama,et al. Gemfibrozil and Its Glucuronide Inhibit the Organic Anion Transporting Polypeptide 2 (OATP2/OATP1B1:SLC21A6)-Mediated Hepatic Uptake and CYP2C8-Mediated Metabolism of Cerivastatin: Analysis of the Mechanism of the Clinically Relevant Drug-Drug Interaction between Cerivastatin and Gemfibrozil , 2004, Journal of Pharmacology and Experimental Therapeutics.
[19] Kairui Feng,et al. The Simcyp® Population-based ADME Simulator , 2009 .
[20] Kazuya Maeda,et al. Physiologically Based Pharmacokinetic Modeling to Predict Transporter-Mediated Clearance and Distribution of Pravastatin in Humans , 2009, Journal of Pharmacology and Experimental Therapeutics.
[21] K. Maeda,et al. Transporter‐Mediated Drug–Drug Interactions Involving OATP Substrates: Predictions Based on In Vitro Inhibition Studies , 2012, Clinical pharmacology and therapeutics.
[22] M. Rowland,et al. Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. , 2006, Journal of pharmaceutical sciences.
[23] Yuichi Sugiyama,et al. Analysis of the Repaglinide Concentration Increase Produced by Gemfibrozil and Itraconazole Based on the Inhibition of the Hepatic Uptake Transporter and Metabolic Enzymes , 2013, Drug Metabolism and Disposition.
[24] Kairui Feng,et al. The Simcyp population-based ADME simulator. , 2009, Expert opinion on drug metabolism & toxicology.
[25] Shelley F. Martin. Bayer pulls cerivastatin (Baycol) from market. , 2001 .
[26] K. Ochmann,et al. Absolute and relative bioavailability of the HMG-CoA reductase inhibitor cerivastatin. , 1997, International journal of clinical pharmacology and therapeutics.
[27] H. Barton,et al. Prediction of Pharmacokinetics and Drug–Drug Interactions When Hepatic Transporters are Involved , 2014, Clinical Pharmacokinetics.
[28] P. Neuvonen,et al. Mechanism‐Based Inactivation of CYP2C8 by Gemfibrozil Occurs Rapidly in Humans , 2011, Clinical pharmacology and therapeutics.
[29] W. Mück. Clinical Pharmacokinetics of Cerivastatin , 2000, Clinical pharmacokinetics.
[30] Masoud Jamei,et al. Cytochrome p450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions. , 2008, Current drug metabolism.
[31] M. Radtke,et al. Biotransformation of cerivastatin in mice, rats, and dogs in vivo. , 1998, Drug metabolism and disposition: the biological fate of chemicals.
[32] K. Pang,et al. Why we need proper PBPK models to examine intestine and liver oral drug absorption. , 2012, Current drug metabolism.
[33] K. Maeda,et al. Prediction of the Overall Renal Tubular Secretion and Hepatic Clearance of Anionic Drugs and a Renal Drug-Drug Interaction Involving Organic Anion Transporter 3 in Humans by In Vitro Uptake Experiments , 2011, Drug Metabolism and Disposition.
[34] K. Maeda,et al. Quantitative Analyses of Hepatic OATP‐Mediated Interactions Between Statins and Inhibitors Using PBPK Modeling With a Parameter Optimization Method , 2016, Clinical pharmacology and therapeutics.
[35] Tim Morris,et al. Physiological Parameters in Laboratory Animals and Humans , 1993, Pharmaceutical Research.
[36] P. Neuvonen,et al. Gemfibrozil greatly increases plasma concentrations of cerivastatin , 2002, Clinical pharmacology and therapeutics.
[37] Yuichi Sugiyama,et al. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. , 2006, Pharmacology & therapeutics.
[38] Yuichi Sugiyama,et al. Virtual Clinical Studies to Examine the Probability Distribution of the AUC at Target Tissues Using Physiologically-Based Pharmacokinetic Modeling: Application to Analyses of the Effect of Genetic Polymorphism of Enzymes and Transporters on Irinotecan Induced Side Effects , 2017, Pharmaceutical Research.
[39] K. Maeda,et al. Comparison of Methods for Estimating Unbound Intracellular-to-Medium Concentration Ratios in Rat and Human Hepatocytes Using Statins , 2017, Drug Metabolism and Disposition.
[40] K. Maeda,et al. Investigation of the Impact of Substrate Selection on In Vitro Organic Anion Transporting Polypeptide 1B1 Inhibition Profiles for the Prediction of Drug-Drug Interactions , 2015, Drug Metabolism and Disposition.
[41] Osamu Okazaki,et al. Human Pharmacokinetic Prediction of UDP-Glucuronosyltransferase Substrates with an Animal Scale-Up Approach , 2011, Drug Metabolism and Disposition.
[42] Yuichi Sugiyama,et al. Inhibition of Transporter-Mediated Hepatic Uptake as a Mechanism for Drug-Drug Interaction between Cerivastatin and Cyclosporin A , 2003, Journal of Pharmacology and Experimental Therapeutics.
[43] H. Brewer,et al. Benefit-risk assessment of Rosuvastatin 10 to 40 milligrams. , 2003, The American journal of cardiology.
[44] Akihiko Konagaya,et al. Estimation of feasible solution space using Cluster Newton Method: application to pharmacokinetic analysis of irinotecan with physiologically-based pharmacokinetic models , 2013, BMC Systems Biology.